Wells Fargo & Company Issues Positive Forecast for Bausch + Lomb (NYSE:BLCO) Stock Price

Bausch + Lomb (NYSE:BLCO) had its price target upped by analysts at Wells Fargo & Company from $17.00 to $18.00 in a report released on Thursday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price target indicates a potential upside of 1.25% from the company’s current price.

A number of other research firms also recently commented on BLCO. Royal Bank Of Canada increased their price objective on shares of Bausch + Lomb from $19.00 to $21.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 27th. Stifel Nicolaus set a $16.00 target price on Bausch + Lomb in a report on Thursday. Citigroup restated a “buy” rating on shares of Bausch + Lomb in a research note on Thursday. Raymond James Financial reaffirmed an “outperform” rating and set a $19.00 price target (up previously from $18.00) on shares of Bausch + Lomb in a research report on Thursday, October 30th. Finally, Barclays set a $20.00 price objective on Bausch + Lomb in a report on Thursday. Four analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $17.85.

Bausch + Lomb Stock Up 0.6%

NYSE BLCO traded up $0.11 during trading on Thursday, hitting $17.78. The stock had a trading volume of 97,270 shares, compared to its average volume of 382,027. Bausch + Lomb has a 12 month low of $10.45 and a 12 month high of $17.96. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.98 and a current ratio of 1.51. The company’s 50-day moving average price is $17.04 and its two-hundred day moving average price is $15.81. The company has a market capitalization of $6.30 billion, a PE ratio of -20.43, a P/E/G ratio of 1.03 and a beta of 0.61.

Bausch + Lomb (NYSE:BLCO) last posted its quarterly earnings data on Wednesday, February 18th. The company reported $0.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.03). Bausch + Lomb had a negative net margin of 6.13% and a positive return on equity of 2.42%. The business had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.38 billion. During the same quarter last year, the business earned $0.25 earnings per share. Bausch + Lomb’s revenue for the quarter was up 9.8% on a year-over-year basis. As a group, sell-side analysts forecast that Bausch + Lomb will post 0.74 EPS for the current year.

Institutional Trading of Bausch + Lomb

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Bausch + Lomb by 729.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock worth $30,000 after acquiring an additional 2,042 shares during the period. Caitong International Asset Management Co. Ltd lifted its position in shares of Bausch + Lomb by 104.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock worth $38,000 after purchasing an additional 1,136 shares in the last quarter. FNY Investment Advisers LLC boosted its position in Bausch + Lomb by 93.8% in the 2nd quarter. FNY Investment Advisers LLC now owns 6,200 shares of the company’s stock valued at $80,000 after buying an additional 3,000 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Bausch + Lomb by 31.2% during the 4th quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock worth $101,000 after purchasing an additional 1,403 shares during the last quarter. Finally, Gruss & Co. LLC acquired a new stake in Bausch + Lomb in the second quarter valued at $130,000. Institutional investors and hedge funds own 11.07% of the company’s stock.

Key Bausch + Lomb News

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Revenue topped estimates and management reiterated full-year revenue guidance of roughly $5.4B–$5.5B, supporting growth expectations and helping shares rise despite the EPS miss. Read More.
• Positive Sentiment: Company framed the quarter as part of a “record year” and signaled a push toward profitable growth on the conference call — messaging that reassures investors focused on margin recovery and sustainable revenue expansion. Read More.
• Positive Sentiment: Management highlighted product innovation initiatives (CEO promoted a new contact-lens technology) and internal incentives tied to AI literacy, which investors may view as long-term catalysts for differentiation and efficiency. Read More. Read More.
• Neutral Sentiment: Stifel Nicolaus maintained a Hold rating on BLCO — a sign of mixed analyst views that can temper volatility but not strongly move consensus. Read More.
• Neutral Sentiment: Full earnings call transcripts and recaps are available for detail on segment performance and margin drivers; these are useful for investors digging into the drivers behind the top-line beat. Read More. Read More.
• Negative Sentiment: EPS missed consensus ($0.32 vs. $0.35) and the company reported a negative net margin for the quarter, which raises near-term profitability concerns and explains part of analyst caution. Read More.
• Negative Sentiment: Bank of America reiterated a Sell rating and set a $15 price target, citing structural and margin headwinds — a high-profile negative analyst view that could cap upside until margins visibly improve. Read More.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.